Top

International Journal of Clinical Pharmacy

Published in:

01-10-2015 | Editorial

Is your love in vain? On associations between genotypes, drug concentrations and clinical outcomes in pharmacogenomic research

Author: Per Damkier

Published in: International Journal of Clinical Pharmacy | Issue 5/2015

Excerpt

In this issue of IJCP, Chawla et al. [1] report on an association between CYP2C19 genotype and plasma voriconazole levels. Based on retrospective data on voriconazole dose, plasma concentration levels, and CYP2C19 genotypes in 55 patients, the authors conclude, “…voriconazole monitoring and genotype analysis may assist in clinical practice and better patient care”, and suggest impact on clinical practice: “CYP2C19 genotype and voriconazole monitoring at initiation……is required to achieve therapeutic targets”. …

Chawla PK, Nanday SR, Dherai AJ, Soman R, Lokhande RV, Naik PR, Ashavaid TF. Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians. IJCP-D-14-00610R2.

Attia J, Ioannidis JP, Thakkinstian A, McEvoy M, Scott RJ, Minelli C, Thompson J, et al. How to use an article about genetic association: B: are the results of the study valid? JAMA. 2009;301:191–7.CrossRefPubMed

Attia J, Ioannidis JP, Thakkinstian A, McEvoy M, Scott RJ, Minelli C, Thompson J, et al. How to use an article about genetic association: C: what are the results and will they help me in caring for my patients? JAMA. 2009;301:304–8.CrossRefPubMed

Kalia M. Biomarkers for personalized oncology: recent advances and future challenges. Metabolism. 2015;64:16–21.CrossRef

Rodríguez-Antona C, Taron M. Pharmacogenomic biomarkers for personalized cancer treatment. J Intern Med. 2015;277:201–17.CrossRefPubMed

Van Ness B. Applications and limitations in translating genomics to clinical practice. Transl Res. 2015. doi:10.1016/j.trsl.2015.04.012.

Daly AK, Cascorbi I. Opportunities and limitations: the value of pharmacogenetics in clinical practice. Br J Clin Pharmacol. 2014;77:583–6.PubMedCentralCrossRefPubMed

Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, Howard SC, et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol. 2015;55:89–106.CrossRefPubMed

Janssens AC, Deverka PA. Useless until proven effective: the clinical utility of preemptive pharmacogenetic testing. Clin Pharmacol Ther. 2014;96:652–4.CrossRefPubMed

10.

Rubin R. Precision medicine: the future or simply politics? JAMA. 2015;313:1089–91.CrossRefPubMed

11.

Joyner MJ, Paneth N. Seven questions for personalized medicine. JAMA. 2015. doi:10.1001/jama.2015.7725. [Epub ahead of print] PubMed PMID: 26098474.

12.

Jameson JL, Longo DL. Precision medicine—personalized, problematic, and promising. N Engl J Med. 2015;372:2229–34.CrossRefPubMed

13.

Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, et al. EU-PACT group. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369:2294–303.CrossRefPubMed

14.

Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, et al. COAG investigators. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369:2283–93.PubMedCentralCrossRefPubMed

15.

Schork NJ. Personalized medicine: time for one-person trials. Nature. 2015;520:609–11.CrossRefPubMed

Title: Is your love in vain? On associations between genotypes, drug concentrations and clinical outcomes in pharmacogenomic research
Author: Per Damkier
Publication date: 01-10-2015
Publisher: Springer Netherlands
Published in: International Journal of Clinical Pharmacy / Issue 5/2015
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI: https://doi.org/10.1007/s11096-015-0167-3

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Is your love in vain? On associations between genotypes, drug concentrations and clinical outcomes in pharmacogenomic research

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2015

ESCP–SFPC international workshop acquisition of pharmaceutical skills: simulation, serious games, innovative approaches 22–23 June 2015, Nice, France

Suboptimal antimicrobial drug exposure in patients with renal impairment

Developing and testing evidence-based weight management in Australian pharmacies: A Healthier Life Program

Pharmacists performing quality spirometry testing: an evidence based review

Patients’ reasons for accepting a free community pharmacy asthma service

Interprofessional communication training: benefits to practicing pharmacists

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page